Ileana Tandron, MD
Endocrinology, Diabetes & Metabolism · Slidell, LANPI 1083614879
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $166,300 of the $204,906 with a category attached, or 81.2%. Novo Nordisk accounts for 97.4% of it on its own, with 38 other manufacturers making up the rest. Reporting peaked in 2019 at $57,163 and has fallen 56.0% since, to $25,177 in 2024. Among endocrinology, diabetes & metabolism clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 549 payments — averaging $373.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$200K
- Grifols USA, LLC$520
- Abbott$443
- Lilly USA, LLC$380
- Boehringer Ingelheim$355
- AbbVie$342
- plus $3K from 33 others
Across 2,878 payments — averaging $201.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$580K
What the payments were for
- Speaking & faculty fees$166,30081%
- Travel & lodging$27,95914%
- Food & beverage$10,5925%
- Education$550%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 242 | $199,561 |
| Grifols USA, LLC | 25 | $520 |
| Abbott | 28 | $443 |
| Lilly USA, LLC | 24 | $380 |
| Boehringer Ingelheim | 24 | $355 |
| AbbVie | 20 | $342 |
| Amgen(2 entities) | 19 | $327 |
| IBSA Pharma Inc. | 17 | $302 |
| AstraZeneca | 17 | $273 |
| Kowa Pharmaceuticals America, Inc. | 15 | $262 |
| Jazz Pharmaceuticals Inc. | 13 | $260 |
| Amneal Pharmaceuticals LLC | 15 | $254 |
| Lifescan, Inc. | 16 | $248 |
| Amarin Pharma, Inc. | 9 | $159 |
| Dexcom, Inc. | 2 | $150 |
| Sanofi-aventis U.S. LLC | 9 | $148 |
| Xeris Pharmaceuticals, Inc. | 7 | $141 |
| Mylan Specialty L.p. | 9 | $140 |
| Merck | 6 | $95 |
| Bayer | 5 | $87 |
| Axsome Therapeutics, Inc. | 2 | $54 |
| Embecta Corp. | 3 | $50 |
| Novartis | 2 | $35 |
| BD | 2 | $32 |
| Shire North American Group Inc | 2 | $29 |
| Johnson & Johnson | 2 | $27 |
| Kyowa Kirin, Inc. | 1 | $24 |
| BETA Bionics, Inc. | 2 | $23 |
| Corcept Therapeutics | 1 | $22 |
| GSK | 1 | $21 |
| Insulet Corporation | 1 | $20 |
| Mannkind Corporation | 1 | $20 |
| Rochester Medical Corporation | 1 | $17 |
| Inogen, Inc. | 1 | $16 |
| Inspire Medical Systems, Inc. | 1 | $16 |
| Medtronic | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Ascendis Pharma Endocrinology Inc | 1 | $13 |
| Eisai Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$75,901
- RYBELSUS$74,562
- Tresiba$18,423
- DEXCOM G6 TRANSMITTER$144
How this compares
$204,906 in reported general payments places this provider in the 90th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
See all endocrinology, diabetes & metabolism providers in Louisiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 256 | $428,349 |
| JardianceEmpagliflozin | 114 | $139,087 |
| MounjaroTirzepatide | 88 | $128,754 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 96 | $120,459 |
| Tresiba Flextouch U-200Insulin Degludec | 54 | $53,010 |
| FarxigaDapagliflozin Propanediol | 52 | $50,066 |
| SynthroidLevothyroxine Sodium | 400 | $42,137 |
| Tresiba Flextouch U-100Insulin Degludec | 74 | $41,059 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 34 | $28,162 |
| JanuviaSitagliptin Phosphate | 16 | $25,458 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $21,544 |
| Xigduo XrDapaglifloz Propaned/Metformin | 34 | $20,668 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 14 | $17,699 |
| VascepaIcosapent Ethyl | 22 | $15,564 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $14,928 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $199,561 | $428,349256 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $355 | $259,546210 claims |
| Lilly USA, LLCMounjaro | $380 | $128,75488 claims |
| AstraZenecaFarxiga | $273 | $50,06652 claims |
| AbbVieSynthroid | $342 | $42,137400 claims |
| MerckJanuvia | $95 | $25,45816 claims |
| Amneal Pharmaceuticals LLCUnithroid, Levothyroxine Sodium | $254 | $16,349331 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
Other endocrinology, diabetes & metabolism in Slidell
- Madelyn WiegandSlidell$11K
- Timothy GilbertBaton Rouge$985K
- Vivian FonsecaNew Orleans$658K
- Abdul KhanHammond$587K
- Marideli ScanlanMarrero$444K
- Justin FontenotLafayette$397K
- Lane FreyThibodaux$202K
- Laura Kimball RavariBossier City$165K
- Lawrence BlondeNew Orleans$142K
- Harold MillerHammond$73K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.